MCC Office of Translational Science Sparkathon |
Wednesday, February 7, 2024 | 10am-5:30pm | Goldberg |
Join us for our first annual Office of Translational Science Retreat, "Sparkathon"! This event aims to “spark” collaborative translational efforts and foster networking among researchers across diverse disciplines and programs. Our keynote speaker, Dr. Himisha Beltran from the Dana-Farber Cancer Institute, a distinguished medical oncologist, and physician-scientist, will share insights into treatment resistance mechanisms in prostate cancer and lineage plasticity during cancer evolution. The keynote and associated panel discussion will provide valuable insights on vital translational processes, featuring an interactive Q&A. The retreat includes a community-scientist program, rapid-fire translational science talks, structured networking sessions, and an exciting opportunity to competitively pitch your translational concept for potential seed funding. Don't miss this chance to be part of a dynamic and collaborative scientific experience!
|
UC San Diego’s Bioengineering Team Uses TSCC at SDSC for Bioinformatics Tool |
The Triton Shared Computer Cluster (TSCC) at the San Diego Supercomputer Center (SDSC) at UC San Diego was recently used by a team of researchers to develop and test SigProfilerMatrixGenerator, a novel bioinformatics tool, that can classify and visualize large-scale mutational events – mutations that affect more than 50 DNA base pairs.
|
SAVE THE DATE | Moores Cancer Center Delivering Discoveries Scientific Retreat |
September 4th, 2024 | 7:30 a.m. to 6:00 p.m. |
Organizers:
Silvio Gutkind, PhD, Chair
Elena Martinez, PhD, Co-chair
Rana McKay, MD, Co-chair
Mark Garcia, Co-chair
Angela Ballantyne, PhD, Co-chair
|
|
|
February 6, 2024 | 12:00 p.m.
Leichtag Biomedical Research Building Room 107
|
February 12, 2024 | 4:00 p.m.
Goldberg Auditorium
|
February 13, 2024 | 12:00 p.m.
Comer Commons
|
February 13, 2024 | 12:00 p.m.
Leichtag Biomedical Research Building Room 107
|
|
|
Moores Cancer Center Speed Mentoring Workshop |
Thursday, February 8, 2024 | 1:00 to 2:00 p.m. |
Join Drs. Pamela Maher, Claude Sirlin and Carrie House to gain expert advice from UC San Diego, San Diego State University, and Salk Institute for Biological Studies faculty members. All students, postdocs, and junior faculty are welcome to attend!
|
Cancer Cell Signaling & Communication (CCSC) Training Program |
Dr. Jing Yang and Dr. Dan Donoghue are opening the call for nominations for the NCI T32 Training Grant in Cancer Cell Signaling & Communication Program. They are looking for outstanding postdoctoral trainees working on cancer research projects from your lab. All trainees accepted into their program are expected to have strong and diverse backgrounds in cancer biology, biochemistry, molecular and cell biology, chemistry, or bioengineering. Nominations for the training program must be submitted by
February 19, 2024.
|
Surgical Oncologists As Scientists (SOAS) Training Program |
As a member of the next generation of translational surgeon-scientists, you will undergo rigorous training in three disciplines: 1) the tumor microenvironment; 2) techniques of biobanking; and 3) innovation and entrepreneurship. This is a truly unique, one of a kind training program, and is located at an elite institution with a Training Faculty composed of 18 NIH-funded ($28.1 million per year; $18.5 million in direct costs) Faculty Mentors.
Applications must be submitted by March 1, 2024.
|
Cancer Therapeutics Training (CT2) Training Program |
The CT2 Program is open to both MDs and PhDs and provides an intensive 2-year period of research and training in the development of novel cancer therapeutics or diagnostics at the Moores Cancer Center. Trainees not only execute a research program under the direction of a member of the faculty of this Comprehensive Cancer Center, but also participate in coursework, seminars, and lectures. Graduates of the program are prepared to transition to leadership roles in cancer therapeutics development in either an academic or commercial environment.
Applications must be submitted by March 15, 2024.
|
Dr. Maryam Ahmadian Memorial Summer Fellowship Program |
Summer research fellowships are available in Metabolic Disease for deserving and committed UCSD undergraduates focused on obesity, diabetes, and related disorders. Ten week stipends will be available for selected candidates to work in laboratories at UCSD or the Salk Institute led by principal investigators who are members in good standing of the UCSD Diabetes Research Center.
Applications are due on March 1, 2024, and should be emailed to saltieladmin@health.ucsd.edu
|
|
|
FEATURED FUNDING OPPORTUNITIES |
The Lung Cancer Research Program (LCRP) released a pre-announcement for the following funding opportunities:
|
- Career Development Award
- Concept Award
- Idea Development Award
- Patient-Centered Outcomes and Survivorship Award
- Translational Research Award
|
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will support investigator-initiated research for both analytical and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays.
Next Deadline: February 20, 2024 (Standard NIH Due Dates Apply)
|
The NCI is providing this opportunity to support supplemental proposals to implement and evaluate promising clinical trial recruitment and retention tools and strategies for cancer screening, prevention, and symptom management clinical trials, as well as quality-of-life studies embedded within treatment and imaging studies. Some examples of potential outcomes include percentage of achievement of pre-specified goals for diverse contacts and accrued participants and meeting recruitment and retention milestones in the predicted accrual period as well as results of participant surveys, staff feedback surveys, focus group reports, comparison with past recruitment performance, pre- and post-test results of participant or staff education programs,
Deadline: Wednesday, February 28, 2024
|
This seed grant funding opportunity supports preliminary findings and exploratory new concepts in early to late- stage gene therapy-related programs. Our aim is to help bridge critical gaps between good ideas and breakthrough discoveries by fostering collaborative interactions to expedite the translation of research into therapeutic treatments. Up to $100K will be awarded per project over a one-year term.
Deadline: Friday, March 1, 2024
Questions? Contact GTI_admin@health.ucsd.edu
|
|
|
|
| EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma |
Michael G. Rosenfeld, MD
Structural and Functional Genomics
|
|
|
|
|
Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma |
Nicholas Webster, PhD
Structural and Functional Genomics
|
|
|
|
|
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study |
Rohit Loomba, MD
Cancer Control Program
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
IMGN853-0421: Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination with Bevacizumab versus Bevacizumab Alone as Maintenance Therapy for Patients with FR-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second-line Platinum-based Chemotherapy plus Bevacizumab (GLORIOSA) |
PI: Ramez Eskander, MD
NCT: NCT05445778
|
STK-012-101: A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK012 Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors |
PI: Rana McKay, MD
NCT: NCT05098132
|
AK112301: A Randomized, Double-blind, Multicenter, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFRTKI Treatment |
PI: Lyudmila Bazhenova, MD
NCT: NCT05184712
|
DCC-2618-03-003: An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With KIT Exon 11 and Cooccurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated With Imatinib |
PI: Adam Burgoyne, MD, PhD
NCT: NCT05734105
|
ZB012-03-002: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety and Dose Confirmation Run-In Period, To Evaluate the Efficacy and Safety of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SAPHIARE) |
PI: Anthony Nguyen
NCT: NCT05786573
|
CLINCIAL TRIALS OFFICE TRANSFORMATION INITIATIVE |
-
The first role-specific training session for Clinical Research / Data Coordinators will take place on Thursday, February 8th. This session will be focused on pre-screening and informed consent best practices and will include a demonstration of pre-screening using real patient examples. If you are not able to attend these training sessions in person, please reach out to your direct supervisor.
-
PI Research KPIs are approved by UCSD and Compliance leadership and are nearing completion to be rolled out for regular reviews of faculty contributions in clinical research (including patient accrual, trial authorship / activation and scientific involvement).
-
The CTO Fast Lane initiative has resulted in accelerated activation of 30 trials to date through the outstanding efforts of our SWAT team – congratulations to all those involved! Additional eligible trials are identified via the Disease Team Approval Form and slated into Fast Lane based on capacity.
-
Keep the feedback coming! With the CTO Relaunch, we encourage you to continue providing your valuable feedback and insights as they play an essential role in our ongoing efforts to enhance the CTO infrastructure, operations and experience. We have an anonymous survey available for you to submit feedback: Access the survey via this link.
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT |
Jackie Robinson Family YMCA Monthly Health Fair |
February 7, 2024 | 10:00 a.m. to 3:00 p.m. |
|
|
Connect with the community this Wednesday, February 7th at the Jackie Robinson YMCA (151 Ymca Way, San Diego, CA 92102) at their monthly health fair! This event provides free health screenings, social services and food resources to all attendees. The Community Outreach & Engagement team will be there sharing cancer prevention education and resources. Email the COE at mcccoe@health.ucsd.edu for more information!
View Flyer
|
2nd Annual Cervical Cancer Awareness Summit Recap |
This past Monday, the Community Outreach & Engagement team hosted their 2nd Annual Cervical Cancer Awareness Summit! With over 70 attendees, this summit provided an update on the current state of cervical cancer and our progress towards ending the burden in our San Diego community!
|
Moores Cancer Center COE at San Diego’s Immunization Coalition Meeting |
As Cervical Cancer Awareness Month draws to a close, the Community Outreach & Engagement team was fortunate to spotlight the cancer during San Diego's Immunization Coalition meeting! Over 100 clinicians and public health professionals tuned in to hear about the current state of cervical cancer and the progress being made in HPV vaccinations both at the national and state level.
|
Cancer Health Equity Collaborative Mixer Recap |
In case you missed it! The Community Outreach & Engagement team hosted their first in-person mixer of the year for their Cancer Health Equity Collaborative workshop. Thank you to all those who were able to make it. Keep an eye out for our next virtual meeting in March; link coming soon!
|
Black History Month Kickoff Recap |
The Community Outreach & Engagement team joined San Diego County's African American/Black Outreach workgroup to kick off Black History Month. COE presented on the current cancer burden in the community and strategies to address disparities.
|
|
|
EQUITY, DIVERSITY AND INCLUSION (EDI) |
2024 Health Disparities Research Institute Application Period Opens Soon! |
Applications for the 2024 Health Disparities Research Institute (HDRI) will be accepted from February 5 – March 11, 2024. HDRI will take place on August 6 – 9, 2024 and is a unique weeklong program that supports the research career development of promising early-career minority health and health disparities research scientists.
Learn More
|
NCI Postdoc Recruitment Event (PRE) |
PRE is a 2-day, in-person event held on May 1-2, 2024, at the National Institutes of Health (NIH). PRE provides Ph.D. candidates the opportunity to explore postdoctoral opportunities and determine if the National Cancer Institute (NCI) is an ideal fit for their professional goals.
A pre-application webinar for the PRE program will be held on Tuesday, January 23, 2024 from 2:30 - 3:30 p.m. ET. Register Now. Application deadline is Wednesday, February 7, 2024.
Apply Now
|
Spring 2024 Faculty Writing Retreat |
March 25 - 26, 2024 | 9:00 a.m. to 4:00 p.m. |
Make progress on writing projects in a supportive community with other faculty! This 2-day retreat is organized by the Center for Faculty Diversity and Inclusion and facilitated by Chrissy Sharp, Director of Writing and Communication Learning Services at the Commons. Enrollment in the retreat includes facilitation, meals, optional writing consults, and support for dependent care. Applications are due on February 20, 2024.
Apply Now
|
|
|
|
